Skip to main content
Category

News Archive

Novavax Logo

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

By News, News Archive

Novavax LogoGAITHERSBURG, Md.May 5, 2025 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals and royalties on net sales earned every season moving forward.

Read More
showcase250

Successful 2nd Annual “Stem Cell and Regenerative Medicine Tech Showcase” Held on April 29, 2025

By News, News Archive

showcase250Innovators in Regenerative Medicine Gathered to Drive Healing and Hope

BALTIMORE, MD. | May 6, 2025 – The Maryland Stem Cell Research Fund (MSCRF) in collaboration with the Maryland Department of Commerce capped off a successful Tech Showcase featuring nearly 200 companies, entrepreneurs, scientists, investors, and other stakeholders from the regenerative medicine sector. All gathered to share breakthroughs and forge new collaborations within Maryland’s vibrant biotech ecosystem. The event spotlighted cutting-edge stem cell technologies poised to become the cures of tomorrow.

The day kicked off at the Rita Rossi Colwell Center in Baltimore with opening remarks from Ruchika Nijhara, MSCRF’s executive director. Nijhara emphasized Maryland’s legacy of pioneering stem cell research and innovation. “Maryland has a proud history of leading groundbreaking discoveries in stem cell science. As the second-largest state-supported fund nationally, MSCRF is instrumental in funding innovators who are transforming research into real, impactful solutions, reinforcing our state’s leadership in regenerative medicine.”

Keynote addresses by Michael Lehmicke, Senior VP at the Alliance for Regenerative Medicine, and Dr. Jay Perman, Chancellor of the University System of Maryland, highlighted the field’s promising future and underscored the critical role of public-private partnerships in accelerating breakthroughs.

The event featured a lively debate between Patrick Hanley from Children’s National Hospital and Jessica Carmen from RoslinCT on the merits of localized versus centralized manufacturing in regenerative medicine—sparking engaging discussions among attendees.

Read More
PQE Group

PQE Group US Earns Great Place to Work Certification™

By News, News Archive

PQE GroupFor its fourth consecutive year, the company is recognized with this certification

Rockville, MD, May 5, 2025. PQE Group is proud to announce that, for the fourth consecutive year, its US subsidiary has been Certified™ by Great Place To Work®. This prestigious award is based entirely on what current employees say about their experience working at PQE Group US. This year, 92% of survey respondents in the US said it’s a great place to work. To obtain this recognition, PQE Group’s US employees completed a voluntary survey, responding to numerous questions regarding their satisfaction in a wide array of areas surrounding PQE Group’s company culture, including leadership behaviors and support, collaboration, inclusion, integrity, communication, and more.

Great Place to Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.

Read More
UMBLD

UMSOM: New Innovation Alliance Aims to Drive New Med Tech Ventures In Region

By News, News Archive

UMBLDApril 28, 2025 | Jon Kelvey – A new collaboration bringing entrepreneurs and investors together with physician-scientists, surgeons, and medical technologists promises to launch the Baltimore region as a major national hub for new biomedical ventures and start-up companies. The initiative, called the “Innovation Alliance,” leverages the region’s national and international leadership in biomedical research and technology to attract venture capital, foster startups, drive economic growth, and ultimately bring to market new treatments, cures, and technologies that will directly improve lives.  

Read More
VerimmuneLogo 01

VerImmune Awarded ~$470K CDMRP Grant to Drive Innovation in ViP-Based Therapeutics for Advanced Melanoma

By News, News Archive

VerimmuneLogo 01Washington DC & Singapore – April 29th, 2025- VerImmune, Inc. (“VerImmune”), a biotechnology company developing innovative Virus-inspired Particle (ViP) modalities, announced today it has been awarded a ~$470,000 USD research grant (MRP Idea Award) from the U.S. Department of Defense (DoD) Melanoma Research Program (MRP), managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

The award will support the development of novel candidates based on VerImmune’s ViP technology for the treatment of advanced or rare melanoma cancers.

Read More
Emergent

Emergent BioSolutions Announces Agreement to Supply the Ontario Ministry of Health with NARCAN®

By News, News Archive

EmergentWINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the Ontario Ministry of Health with NARCAN® Nasal Spray for the Ontario Naloxone Program (ONP). Since 2018, Emergent has supported the Ontario Ministry of Health to provide access to NARCAN® Nasal Spray across the province. NARCAN® Nasal Spray is designed to reverse the effects of an opioid poisoning in minutes and is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years (48 months).

Read More
NeopendaSona

Beyond the Device: Neopenda’s Human-Centered Approach to Health Tech

By News, News Archive

NeopendaSonaMore than a decade ago, a young engineer named Sona Shah stepped into a classroom in rural Kenya—and the beginning of a life-changing journey. What she witnessed there didn’t just shape her understanding of global health disparities; it set her on a path to build solutions for those often left behind. Today, as CEO and Co-Founder of Neopenda, Shah is leading a growing team that’s redefining how clinical care is delivered in low-resource settings around the world. The company’s mission is simple but urgent: develop innovative, sustainable medical technologies that make high-quality care accessible to everyone.

Shah’s inspiration for Neopenda was born from lived experience. After earning her degree in chemical engineering, she spent time teaching in western Kenya, where preventable illness and lack of access to healthcare were daily realities. “That experience planted a seed,” she said. “I couldn’t stop thinking about the kids I had taught, and the families around them who deserved more.” Returning to the U.S., Shah pursued a master’s in biomedical engineering at Columbia University, where she met her co-founder, Teresa Cauvel. A needs-assessment trip to Uganda exposed the two to hospitals filled with critically ill newborns, overwhelmed nurses, and donated medical equipment that sat broken and unused. “It became crystal clear that the issue wasn’t just a lack of resources—it was a lack of thoughtful design,” she said.

This realization laid the foundation for neoGuard™, Neopenda’s flagship product: a wearable, clinical-grade vital signs monitor designed for low-resource environments. “We didn’t want to create just another device—we wanted to build something with and for the clinicians on the frontlines,” Shah explained. Designed to monitor heart rate, respiratory rate, oxygen saturation, and temperature, neoGuard is battery-powered, lightweight, and built to function in settings where reliable power and infrastructure are not guaranteed.

Read More
Rooster

RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing

By News, News Archive

RoosterFREDERICK, Md.April 30, 2025 /PRNewswire/ — RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease.

Read More
Sonavex

Sonavex Receives FDA 510(k) Clearance for EchoMap™ Device

By News, News Archive

SonavexBaltimore, MD (April 28th, 2025) – Sonavex, Inc., a privately held medical device company with ultrasound technologies that deliver quantitative blood flow and other critical vascular data at the point of care, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s EchoMap™ device. Sonavex’s EchoMap leverages 3D ultrasound and AI algorithms to empower dialysis technicians without prior ultrasound experience to visualize the target fistula or graft before cannulation.

Read More
Clasp logo full color RGB

Clasp Therapeutics Begins First Human Trial of New Immune Therapy Designed to Precisely Attack Cancer Cells

By News, News Archive

Clasp logo full color RGBClasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

CAMBRIDGE, Mass. & ROCKVILLE, Md.–(BUSINESS WIRE)–Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T-cell engagers (TCEs), today announced dosing of the initial patient in the GUARDIAN-101 phase 1 trial of CLSP-1025, the first tumor-specific TCE to enter clinical development. CLSP-1025 exclusively targets cancer cells expressing the p53R175H mutation, a mutation associated with a wide range of solid tumors, including colorectal, pancreatic, lung, gastric, esophageal, gynecological, and prostate cancers.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.